{"entity":{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial testing JSKN003 in HER2-positive breast cancer, now recruiting.","summary":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer is a phase 3 interventional study registered as NCT06846437, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects. Planned enrolment is 228 participants (estimated). The study started in 2025-02-18 and primary completion is expected in 2026-10-13. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06846437","url":"https://clinicaltrials.gov/study/NCT06846437"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["jskn003"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06846437","phase":"3","setting":"A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects","sponsor":"Shanghai JMT-Bio","started":"2025-02-18","startedType":"actual","enrolled":228,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06846437/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}